A Survey of Genome Editing Activity for 16 Cas12a Orthologs
Name
nihms-1063014.pdf
Description
Accepted version
Size
886.09 KB
Format
Unknown
Checksum (MD5)
733e6940b78546af5e71ea939c5d908e
Author(s)
Zetsche, Bernd
Abudayyeh, Omar O.
Gootenberg, Jonathan S
Scott, David Arthur
Zhang, Feng
Date Issued
2020
Journal
The Keio Journal of Medicine
Publisher
Keio Journal of Medicine
Citation
Zetsche, Bernd, Abudayyeh, Omar O, Gootenberg, Jonathan S, Scott, David A and Zhang, Feng. 2020. "A Survey of Genome Editing Activity for 16 Cas12a Orthologs." The Keio Journal of Medicine, 69 (3).
Version
Author's final manuscript
Abstract
© 2019 by The Keio Journal of Medicine. The class 2 CRISPR-Cas endonuclease Cas12a (previously known as Cpf1) offers several advantages over Cas9, including the ability to process its own array and the requirement for just a single RNA guide. These attributes make Cas12a promising for many genome engineering applications. To further expand the suite of Cas12a tools available, we tested 16 Cas12a orthologs for activity in eukaryotic cells. Four of these new enzymes demonstrated targeted activity, one of which, from Moraxella bovoculi AAX11_00205 (Mb3Cas12a), exhibited robust indel formation. We also showed that Mb3Cas12a displays some tolerance for a shortened PAM (TTN versus the canonical Cas12a PAM TTTV). The addition of these enzymes to the genome editing toolbox will further expand the utility of this powerful technology.
MIT Department
Broad Institute of MIT and Harvard
McGovern Institute for Brain Research at MIT
Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences
Massachusetts Institute of Technology. Department of Biological Engineering
Harvard University--MIT Division of Health Sciences and Technology
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.2302/KJM.2019-0009-OA
